Canada markets closed

Filament Health Corp. (FLHLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.03770.0000 (0.00%)
At close: 12:16PM EDT

Filament Health Corp.

4475 Wayburne Drive
Unit 210
Burnaby, BC V5G 4X4

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. Benjamin LightburnCo-Founder, CEO & Chairman128.09kN/A1986
Andry TjahyanaVP of Business Development139.07kN/AN/A
Mr. Jonathan ConlinCorporate Secretary & DirectorN/AN/A1985
Mr. Steven Nguyen CPAInterim Chief Financial OfficerN/AN/AN/A
Ms. Lisa RankenChief Operating OfficerN/AN/A1984
Mr. Ryan MossChief Science OfficerN/AN/AN/A
Ms. Anna CordonVice President of Marketing & CommunicationsN/AN/AN/A
Mr. Jeff FellowsHead of RegulatoryN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company. The company propagates psychedelic plants and fungi; conducts genetic research; develops manufacturing technology; generates intellectual property; conducts in-house trials; and distributes drug candidates to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.

Corporate Governance

Filament Health Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.